HCP Live December 31, 2023
Analysis shows that biosimilar uptake was up to 2-fold greater in Medicare Advantage coverage than traditional Medicare.
Biosimilar use is consistently higher in instances of Medicare Advantage insurance versus traditional Medicare, according to data from a new research letter.1
Analysis from a team of federal agency and pharmaceutical industry-based investigators showed that biosimilar uptake was, in the cases of some observed products on the market, up to 2-fold greater in Medicare Advantage coverage than traditional Medicare. The new data supplement prior findings showing significant differences in biosimilar use between managed care versus fee-for-service Medicaid, suggesting a need to investigate the various mechanism that which may inform the discrepancy in market share for cost-efficient biosimilars.
Investigators led by Yoganand Chillarige, MPA,...
Today's Sponsors
Today's Sponsor